OR WAIT null SECS
BMG Pharma's clinical trial has demonstrated positive results in the efficacy of BMG0705 Nasal Spray and BMG0703A Mouth Rinse as treatments for asymptomatic COVID-19 patients.
A clinical trial, conducted by BMG Pharma (a biopharmaceutical and B2B company), has demonstrated positive results in the efficacy of BMG0705 Nasal Spray and BMG0703A Mouth Rinse as treatments for asymptomatic COVID-19 patients, the company reported in a Aug. 2, 2021 press release.
The study, which included a total of 106 people, showed sufficient efficiency of the treatment with the nasal spray and mouth rinse versus placebo in preventing COVID-19—determined with a PCR test. The efficacy of the products is believed to be a result of the combined action of hydrogen peroxide and hyaluronic acid, which form protective barriers in the nasal mucosa and oral mucosa.
Based on the results, the company have suggested that the investigated active intervention may be effective at increasing the rate of negativization of a positive PCR swab test for SARS-CoV-2. However, further research is required to confirm the initial results in certain population subgroups.
Source: BMG Pharma